Literature DB >> 26652031

The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Brian D Adams1,2, Christine Parsons1, Frank J Slack2.   

Abstract

INTRODUCTION: Many RNA species have been identified as important players in the development of chronic diseases including cancer. Certain classes of regulatory RNAs such as microRNAs (miRNAs) have been investigated in such detail that bona fide tumor suppressive and oncogenic miRNAs have been identified. Because of this, there has been a major effort to therapeutically target these small RNAs. One in particular, a liposomal formulation of miR-34a (MRX34), has entered Phase I trials. AREAS COVERED: This review aims to summarize miRNA biology, its regulation within normal versus disease states and how it can be targeted therapeutically, with a particular emphasis on miR-34a. Understanding the complexity of a single miRNA will aid in the development of future RNA-based therapeutics for a broader range of chronic diseases. EXPERT OPINION: The potential of miRNAs to be developed into anti-cancer therapeutics has become an increasingly important area of research. miR-34a is a tumor suppressive miRNA across many tumor types through its ability to inhibit cellular proliferation, invasion and tumor sphere formation. miR-34a also shows promise within certain in vivo solid tumor models. Finally, as miR-34a moves into clinical trials it will be important to determine if it can further sensitize tumors to certain chemotherapeutic agents.

Entities:  

Keywords:  Biomarker; breast cancer; cancer; lung; miR-34; microRNA; therapy; treatment resistance; tumor suppressor

Mesh:

Substances:

Year:  2015        PMID: 26652031      PMCID: PMC4922263          DOI: 10.1517/14728222.2016.1114102

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  102 in total

1.  Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.

Authors:  Arash Javeri; Massoud Ghaffarpour; Masoumeh Fakhr Taha; Massoud Houshmand
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

2.  The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells.

Authors:  Jun Cheng; Lin Zhou; Qin-Fen Xie; Hai-Yang Xie; Xu-Yong Wei; Feng Gao; Chun-Yang Xing; Xiao Xu; Lan-Juan Li; Shu-Sen Zheng
Journal:  Proteomics       Date:  2010-04       Impact factor: 3.984

3.  MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages.

Authors:  Pei Jiang; Ronghua Liu; Yijie Zheng; Xiaoming Liu; Lijun Chang; Shudao Xiong; Yiwei Chu
Journal:  Exp Cell Res       Date:  2012-03-27       Impact factor: 3.905

4.  miRNA-34a is associated with docetaxel resistance in human breast cancer cells.

Authors:  L Kastl; I Brown; A C Schofield
Journal:  Breast Cancer Res Treat       Date:  2011-03-12       Impact factor: 4.872

5.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

6.  MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.

Authors:  Mei-Yi Wu; Junjiang Fu; Xiuli Xiao; Jingbo Wu; Ray-Chang Wu
Journal:  Cancer Lett       Date:  2014-08-27       Impact factor: 8.679

7.  Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer.

Authors:  Christopher L Daige; Jason F Wiggins; Leslie Priddy; Terri Nelligan-Davis; Jane Zhao; David Brown
Journal:  Mol Cancer Ther       Date:  2014-07-22       Impact factor: 6.261

8.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Authors:  Elena Gallardo; Alfons Navarro; Nuria Viñolas; Ramon M Marrades; Tania Diaz; Bernat Gel; Angels Quera; Eva Bandres; Jesus Garcia-Foncillas; Jose Ramirez; Mariano Monzo
Journal:  Carcinogenesis       Date:  2009-09-07       Impact factor: 4.944

9.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.

Authors:  Nora Bandi; Erik Vassella
Journal:  Mol Cancer       Date:  2011-05-16       Impact factor: 27.401

10.  In-depth analysis shows synergy between erlotinib and miR-34a.

Authors:  Jane Zhao; Kevin Kelnar; Andreas G Bader
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

View more
  43 in total

Review 1.  Noncoding RNAs in the Regulatory Network of Hypertension.

Authors:  Gengze Wu; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 2.  Ras and exosome signaling.

Authors:  Rachel E Sexton; Gabriel Mpilla; Steve Kim; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2019-02-12       Impact factor: 15.707

Review 3.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 4.  The Role of Non-coding RNAs in Oncology.

Authors:  Frank J Slack; Arul M Chinnaiyan
Journal:  Cell       Date:  2019-11-14       Impact factor: 41.582

Review 5.  Inflammation and epigenetic regulation in osteoarthritis.

Authors:  Jie Shen; Yousef Abu-Amer; Regis J O'Keefe; Audrey McAlinden
Journal:  Connect Tissue Res       Date:  2016-07-07       Impact factor: 3.417

Review 6.  How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD.

Authors:  Julian Gomez-Cambronero; Kristen Fite; Taylor E Miller
Journal:  Adv Biol Regul       Date:  2017-08-24

7.  Layer-by-layer assembled gold nanoshells for the intracellular delivery of miR-34a.

Authors:  Ritu Goyal; Chintan H Kapadia; Jilian R Melamed; Rachel S Riley; Emily S Day
Journal:  Cell Mol Bioeng       Date:  2018-06-06       Impact factor: 2.321

8.  miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.

Authors:  Anna Maria Grimaldi; Marco Salvatore; Mariarosaria Incoronato
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

9.  Targeting the mutant p53 secretome.

Authors:  Kartik Sehgal; David A Barbie
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

10.  miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.

Authors:  Silvia Martini; Valentina Zuco; Monica Tortoreto; Stefano Percio; Elisa Campi; Rihan El Bezawy; Valentina Doldi; Yosef Landesman; Marzia Pennati; Nadia Zaffaroni
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.